c-Met/HGFR
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB18852 | XL-092 | 2367004-54-2 | XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays. |
| FB18852 | XL-092 | 2367004-54-2 | XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays. |
| FB01931 | Tyrosine Kinase Inhibitor | 1021950-26-4 | Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma. |
| FB09316 | Tivantinib | 905854-02-6 | Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM with little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. |
| FB03013 | SU11274 | 658084-23-2 | SU11274 is a selective Met inhibitor with IC50 of 10 nM, no effects on PGDFRβ, EGFR or Tie2. |
| FB03725 | SGX-523 | 1022150-57-7 | SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM. |
| FB02309 | SCR-1481B1 | 1174161-86-4 | SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. |
| FB16357 | SCR-1481B1 x(NH2(OH)3) | N/A | SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. |
| FB02733 | Savolitinib | 1313725-88-0 | Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50= 5 nM) with potential antineoplastic activity. |
| FB11098 | SAR125844 | 1116743-46-4 | SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity. |
| FB10141 | S49076 | 1265965-22-7 | S49076 is a potent inhibitor of MET, AXL/MER, and FGFRs. |
| FB09625 | PHA-665752 | 477575-56-7 | PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM. |
| FB07163 | PF-04217903 Methanesulfonate | 956906-93-7 | PF-04217903 Methanesulfonate is a highlu selective c-Met inhibitor with IC50 of 4.8 nM. |
| FB03843 | PF-04217903 | 956905-27-4 | PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). |
| FB01125 | NVP-BVU972 | 1185763-69-2 | NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects. |
| FB12961 | Norcantharidin | 29745-04-8 | Norcantharidin is a potential antitumor agent. |
| FB13160 | Ningetinib Tosylate | 1394820-77-9 | Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively. |
| FB02707 | MK-8033 HCl | 1283000-43-0 | MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. |
| FB00952 | MK-8033 | 1001917-37-8 | MK-8033 is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. |
| FB01633 | MK-2461 | 917879-39-1 | MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 0.4-2.5 nM, also inhibits FGFR1/2/3, KDR, TrkA/B, and Flt4 with IC50 of 65/39/50 nM, 44 nM, 46/61 nM, and 78 nM respectively. |
| FB06546 | Merestinib | 1206799-15-6 | LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM. |
| FB02353 | LY2801653 2HCl | 1206801-37-7 | LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase (Ki= 2 nM). |
| FB12033 | JNJ-38877618 | 943540-74-7 | JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively. |
| FB09627 | JNJ-38877605 | 943540-75-8 | JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM. |
| FB08113 | INC28060 | 1029712-80-8 | INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM. |
| FB02439 | Herbacetin | 527-95-7 | Herbacetin, a natural product isolated and purified from the herbs of Equisetum hyemale L. It was found to efficiently block the enzymatic activity of SARS-CoV 3CLpro. |
| FB08332 | Golvatinib | 928037-13-2 | Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM. |
| FB15613 | Glumetinib | 1642581-63-2 | Glumetinib is a novel, potent and highly selective inhibitor of c-Met. |
| FB02272 | Glesatinib HCl | 1123838-51-6 | Glesatinib HCl is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. |
| FB02436 | Foretinib | 849217-64-7 | Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and with little activity to FGFR1 and EGFR. |
| FB08603 | Tepotinib | 1100598-32-0 | EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, > 200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. |
| FB15750 | Dihexa acetate | 2453297-24-8 | Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering. |
| FB16259 | DBPR114 | 2443767-35-7 | DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss. |
| FB16790 | RON-IN-1 | 913376-84-8 | c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner. |
| FB11986 | c-Met-IN-2 | 1635406-73-3 | c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity. |
| FB01067 | c-Met Inhibitor 1 | 1357072-61-7 | c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. |
| FB15234 | PLB-1001 | 1440964-89-5 | Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1]. |
| FB00122 | BMS-794833 | 1174046-72-0 | BMS-794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 1.7 and 15 nM. |
| FB07003 | BMS-777607 | 1025720-94-8 | BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, being 40-fold selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. |
| FB16503 | BAY 474 | 1033767-86-0 | BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe. |
| FB01406 | AMG-458 | 913376-83-7 | AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells. |
| FB02308 | AMG-337 | 1173699-31-4 | AMG-337 is a potent, highly selective and ATP-competitive MET kinase inhibitor with an IC50 of < 5nM in enzymatic assays. |
| FB07009 | AMG-208 | 1002304-34-8 | AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. |
| FB01065 | Altiratinib | 1345847-93-9 | Altiratinib is a c-MET/TIE-2/VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. |